Can-Fite's Latest Innovation: Namodenoson Shows Significant Results in Obesity Reduction
Can-Fite's Latest Innovation: Namodenoson Shows Significant Results in Obesity Reduction
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today reported new data on Namodenoson's anti-obesity mechanism of action.
Can-Fite BioPharma Ltd.（紐約證券交易所代碼：CANF）（TASE：CANF）是一家開發治療腫瘤和炎症性疾病的專有小分子藥物的生物技術公司，今天公佈了有關Namodenoson抗肥胖作用機制的新數據。
New data demonstrate that treatment of fat cells (3T3-L1 adipocytes) with Namodenoson leads to modulation of proteins that increase adiponectin level. Adiponectin is a regulator of fat production in the cells, resulting in the inhibition of fat levels. Furthermore, Namodenoson reduced body weight in an experimental animal model of obesity induced by a high fat diet. In a Phase IIa NASH study, in patients treated with Namodenoson, a 2.1% weight loss was observed after 3 months of treatment (Safadi at Al) and a significant decrease in serum adiponectin levels was found.
新數據表明，使用Namodenoson治療脂肪細胞（3T3-L1 脂肪細胞）會導致蛋白質的調節，從而增加脂聯素水平。脂聯素是細胞中脂肪生成的調節劑，從而抑制脂肪水平。此外，在高脂飲食誘發的肥胖實驗動物模型中，Namodenoson減輕了體重。在一項IIa期NASH研究中，在接受Namodenoson治療的患者中，治療3個月後觀察到體重減輕了2.1％（Safadi at Al），並發現血清脂聯素水平顯著降低。
譯文內容由第三人軟體翻譯。